Back to search results

Digital App for Acute Myeloid Leukemia Patients

This study is testing a new digital app called DREAMLAND to see if it can improve the quality of life and psychological well-being of people with acute myeloid leukemia (AML) who are undergoing intensive chemotherapy. You might be able to join if you are an adult (18-120 years old) who has been diagnosed with AML and are starting intensive chemotherapy or certain other treatments. The study aims to see if using DREAMLAND helps with your quality of life by day 20 of your treatment, as measured by a specific questionnaire. This study is currently unclear on its status.

Study design
This is an interventional study with an estimated enrollment of 200 participants. Participants will be assigned to use either the DREAMLAND app or the VITAL WELLNESS app.
What's involved
If you participate, you will start using your assigned digital app during the first week of hospitalization, aiming to complete one module each week for four weeks.
Compensation
Not stated in the trial record.
Follow-up
Your quality of life will be measured at day 20 after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06472128

Novel Digital Application for Patients With Acute Leukemia

Recruiting
NAAges 18+InterventionalSupportive care
Massachusetts General Hospital
~200 participants
Updated 2025-11-10 on ClinicalTrials.gov
What's tested:DREAMLANDVITAL WELLNESS

At a glance

Recruiting sites
1 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient reported quality of life (QOL) at day 20 as measured by the Functional Assessment of Cancer Therapy-Leukemia scale
Measured over Day +20

Conditions

Relapsed Adult Acute Myeloid Leukemia
Primary Refractory Acute Myeloid Leukemia
High Risk Acute Myeloid Leukemia

Explore related trials

Acute Myeloid Leukemia

Where it's being run

3 sites across 3 states
Massachusetts1
North Carolina1
Washington1

Who to contact

Areej El-Jawahri, MD
[email protected]
617-724-4000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Hospitalized patients (age \> 18 years) with a diagnosis of AML.
Initiating treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen or b) hypomethylating agents (HMA) +/- additional agents or modification of this regimen on a clinical trial.
Ability to comprehend and speak English as the digital apps are only available in English

Exclusion

Patients with a diagnosis of acute promyelocytic leukemia
Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures.

What this trial measures

  • Patient reported quality of life (QOL) at day 20 as measured by the Functional Assessment of Cancer Therapy-Leukemia scaleDay +20

    To compare QOL at day +20 between those receiving DREAMLAND versus VITAL WELLNESS as measured by the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leukemia) at day 20. Higher scores on FACT-Leukemia (range 0-176) indicate a better QOL.